Alluvi, formerly BI 4744, presents a notable development in weight control care. This dual agonist targeting both GLP-1 and GIP sites demonstrates remarkable results in research studies, potentially surpassing current https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/